P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
Justin M. Watts(Sylvester Comprehensive Cancer Center), Pankit Vachhani(University of Alabama at Birmingham), Alessandra Iurlo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Anthony M. Hunter(Emory University), Fred Zheng(Incyte (United States)), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Brandi Reeves(University of North Carolina at Chapel Hill), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Francis Séguy, Rosa Ayala(Hospital Universitario 12 De Octubre), Anna B. Halpern(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Feng Zhou(Nanchang University), Xuejun Chen(Yunnan Academy of Agricultural Sciences), Francesca Palandri(Istituto Oncologico Romagnolo)
Cited by 1
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
|Blood|2014|722
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502